ALCLS
CELLECTIS
Stock Euronext / Paris – Stock Market Prices, News & Analysis
Cellectis is a biotechnology company that uses advanced genetic engineering techniques to develop immunotherapies for cancer.
CELLECTIS
ALCLS
Cellectis is a biotechnology company that uses advanced genetic engineering techniques to develop immunotherapies for cancer.
Price history of CELLECTIS
Price history of CELLECTIS
Performance & Momentum
Strategic Analysis
CELLECTIS • 2026
Cellectis positions itself as an innovative player in the French biotechnology sector, specializing in the development of oncology immunotherapies through advanced genetic modification tools. Its economic model is based on the monetization of its proprietary technologies to treat hard-to-treat cancers, targeting a segment with high medical and commercial potential.
Strengths
- Cutting-edge expertise in genetic engineering applied to oncology
- Strong momentum in a promising immunotherapy market
- French positioning in an innovative biotechnology sector
Weaknesses
- Significant volatility due to the speculative nature of biotech research
- Contrasting and fragile long-term performance history
Momentum
The current momentum reflects a marked resurgence of interest, supported by strong progress over the past year which indicates a positive trend surrounding clinical advancements or partnerships. This calls for close monitoring of short-term developments to confirm a consolidation of valuation potential.
Similar stocks to CELLECTIS
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
